Tixagevimab–cilgavimab intramuscular PK
Reference paper ↗A two-compartment population PK model with intramuscular absorption for the long-acting antibody combination tixagevimab–cilgavimab and covariate-dependent bioavailability and disposition.
- Therapeutic
- Tixagevimab and cilgavimab, AZD7442, tixagevimab, cilgavimab, Evusheld, tixagevimab/cilgavimab
- Modality
- Monoclonal antibody
- Target
- SARS-CoV-2 Spike RBD
- Disease
- SARS-CoV-2 pre-exposure prophylaxis
- Model type
- PopPK
Complete model workspace
Checking workspace access…
- Parameters
- 23
- States
- 5
- Equations
- 5
- Derived outputs
- 8
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
AZD7442 600 mg IM typical gluteal
How do dose, injection site, and patient covariates change tixagevimab–cilgavimab exposure? Explore this intervention regimen through Central antibody concentration, Peripheral antibody concentration, Cumulative antibody exposure, Effective absorption rate.
Starting result
This result reflects the starting settings. Run your changes to update it.
Result preview could not load
The generated result could not be loaded. The inputs remain available below.
Starting configuration
Time: 0–1,000 day; step 1
| Input | Default | Available range |
|---|---|---|
| Systemic clearance | 0.0504 L/day | 0.0252–0.0756 L/day |
| Central distribution volume | 3.36 L | 1.68–5.04 L |
| Intercompartmental clearance | 0.395 L/day | 0.1975–0.5925 L/day |
| Peripheral distribution volume | 1.83 L | 0.915–2.745 L |
| Intramuscular bioavailability fraction | 0.671 dimensionless | 0.3355–1.007 dimensionless |
Expected readouts
Central antibody concentration · Peripheral antibody concentration · Exposure (AUC) (ug*day/mL) · Effective absorption rate
Adjustable model parameters
This public explorer exposes 5 curated parameters. Sign in to edit all 23 declared model parameters.
More key parameters (1)
How the model represents the biology
A two-compartment population PK model with intramuscular absorption for the long-acting antibody combination tixagevimab–cilgavimab and covariate-dependent bioavailability and disposition.
Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.
Model scope: Viral binding, neutralization, infection protection, and distinct simultaneous tixagevimab and cilgavimab species are not represented.
Modeled relationships (7)
- Intramuscular dose → IM depot: IM input (flow)
- IM depot → Central exposure: absorption (flow)
- Central exposure ↔ Peripheral pool: distribution (reversible exchange)
- Central exposure → Systemic clearance: systemic CL (loss)
- Central exposure → Long-duration exposure: integrates C (production)
- Patient + site covariates → IM depot: alters ka (modulation)
- Patient + site covariates → Systemic clearance: alters CL (modulation)
Modeled relationships: Intramuscular dose to IM depot: IM input (flow); IM depot to Central exposure: absorption (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Central exposure to Systemic clearance: systemic CL (loss); Central exposure to Long-duration exposure: integrates C (production); Patient + site covariates to IM depot: alters ka (modulation); Patient + site covariates to Systemic clearance: alters CL (modulation).
Primary readouts: Central antibody concentration; Peripheral concentration; Cumulative exposure; Effective absorption rate.
Related models
Research use only — not for patient-specific prediction or dosing advice.
